Breast density as indicator for the use of mammography or MRI to screen women with familial risk for breast cancer (FaMRIsc): a multicentre randomized controlled trial by Saadatmand, S. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/110433
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
STUDY PROTOCOL Open Access
Breast density as indicator for the use of
mammography or MRI to screen women with
familial risk for breast cancer (FaMRIsc):
a multicentre randomized controlled trial
Sepideh Saadatmand1*, Emiel JT Rutgers2, Rob AEM Tollenaar3, Hermien M Zonderland4, Margreet GEM Ausems5,
Kristien BMI Keymeulen6, Margreet S Schlooz-Vries7, Linetta B Koppert1, Eveline AM Heijnsdijk8, Caroline Seynaeve9,
Cees Verhoef1, Jan C Oosterwijk10, Inge-Marie Obdeijn11, Harry J de Koning8 and Madeleine MA Tilanus-Linthorst1
Abstract
Background: To reduce mortality, women with a family history of breast cancer often start mammography
screening at a younger age than the general population. Breast density is high in over 50% of women younger
than 50 years. With high breast density, breast cancer incidence increases, but sensitivity of mammography
decreases. Therefore, mammography might not be the optimal method for breast cancer screening in young
women. Adding MRI increases sensitivity, but also the risk of false-positive results. The limitation of all previous MRI
screening studies is that they do not contain a comparison group; all participants received both MRI and
mammography. Therefore, we cannot empirically assess in which stage tumours would have been detected by
either test.
The aim of the Familial MRI Screening Study (FaMRIsc) is to compare the efficacy of MRI screening to
mammography for women with a familial risk. Furthermore, we will assess the influence of breast density.
Methods/Design: This Dutch multicentre, randomized controlled trial, with balanced randomisation (1:1) has a
parallel grouped design. Women with a cumulative lifetime risk for breast cancer due to their family history of
≥20%, aged 30–55 years are eligible. Identified BRCA1/2 mutation carriers or women with 50% risk of carrying a
mutation are excluded. Group 1 receives yearly mammography and clinical breast examination (n = 1000), and
group 2 yearly MRI and clinical breast examination, and mammography biennially (n = 1000).
Primary endpoints are the number and stage of the detected breast cancers in each arm. Secondary endpoints are
the number of false-positive results in both screening arms. Furthermore, sensitivity and positive predictive value of
both screening strategies will be assessed. Cost-effectiveness of both strategies will be assessed. Analyses will also
be performed with mammographic density as stratification factor.
Discussion: Personalized breast cancer screening might optimize mortality reduction with less over diagnosis.
Breast density may be a key discriminator for selecting the optimal screening strategy for women< 55 years with
familial breast cancer risk; mammography or MRI. These issues are addressed in the FaMRIsc study including high
risk women due to a familial predisposition.
Trial registration: Netherland Trial Register NTR2789
Keywords: Breast cancer, Familial risk, Screening, MRI, Breast density, Cost-effectiveness
* Correspondence: s.saadatmand@erasmusmc.nl
1Department of Surgery, Erasmus University Medical Centre, Rotterdam,
Netherlands
Full list of author information is available at the end of the article
© 2012 Saadatmand et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Saadatmand et al. BMC Cancer 2012, 12:440
http://www.biomedcentral.com/1471-2407/12/440
Background
A positive family history is one of the most important risk
factors for breast cancer [1]. Women with a family history
of breast cancer are not only at greater risk of developing
breast cancer, but their risk also increases at a younger age
than in the general population [2]. In over 75% of the fam-
ilies that display clear clustering of breast cancer no causa-
tive gene mutation like BRCA1 or BRCA2 can be detected
[3]. Tumour stage at detection is of key influence on sur-
vival [4]. Aiming at early detection and ultimately to re-
duce mortality risk, women, with a positive family history
for breast cancer, are often offered annual screening with
mammography before age 50 [5-7]. However, screening
also causes false-positive test results.
In the last decade several screening trials in high-risk
women have been completed and Magnetic Resonance
Imaging (MRI) had a significantly higher sensitivity for
invasive breast cancer than mammography in all studies
[8-12]. However, MRI was expensive and was associated
with significantly more false-positive results in most
studies. Furthermore, mammography had better sensitiv-
ity for the pre-invasive stage of breast cancer: ductal car-
cinoma in situ (DCIS) [13]. Therefore, mammography
should perhaps not be omitted completely when MRI
screening is offered.
Despite the higher costs of MRI and the false-positive
results, screening with yearly MRI in addition to mam-
mography is considered cost-effective for female BRCA1
and BRCA2 gene mutation carriers aged 30–60 years or
women who have a 50% chance of carrying such a muta-
tion [14-16]. For women with a familial risk, from fam-
ilies without a proven genetic predisposition, results are
inconclusive [17,18]. Since previous screening studies
have performed MRI and mammography simultaneously
the difference in stage of the tumours when detected by
mammography alone is not known. A randomized con-
trolled trial is therefore needed.
Apart from a positive family history and age, high
breast tissue density is a well documented risk factor for
breast cancer. Breast density increases breast cancer in-
cidence significantly [19,20]. At the same time, high
mammographic density impairs the sensitivity of mam-
mography [19-22], but far less the sensitivity of MRI
[23]. The lower sensitivity of mammography in dense
breasts is most likely caused by a masking effect, rather
than by a higher tumour growth rate in denser tissue
[21,24]. Breast density is high or very-high in about
50-74% of women between 40 to 49 years of age,
whereas only 20-44% of women in their 60s have dense
or extremely dense breast tissue [25,26]. This dual effect
of breast density on cancer incidence and sensitivity of
mammography results in women with the highest risk
being screened with a tool with limited effectiveness:
mammography.
To the best of our knowledge, no study has been pub-
lished assessing the cost-effectiveness of MRI specifically
in women with a familial risk for breast cancer, without
a known genetic predisposition. Therefore, guidelines for
breast cancer screening for women with a familial risk
vary widely internationally and are weakly underpinned.
The 2008 American Cancer Society and 2010 American
College of Radiologists guidelines advise MRI screening
for women with a familial cumulative lifetime risk
(CLTR) > 20% [18], while the Dutch guidelines advise
screening with mammography only [17].
Robust cost-effectiveness analyses cannot be based on
the published studies, as all had a paired design (i.e. all
participants received both mammography and MRI).
These studies cannot examine the improvement in
tumour stage at diagnosis, as one cannot know in what
stage the tumour would have been diagnosed by either
test alone. A randomized controlled trial is needed for a
valid answer to these questions.
Furthermore, cost-effectiveness of either imaging tech-
nique may vary across categories of mammographic dens-
ity. Breast density has not yet been evaluated as a
parameter to identify sub-groups of women with a familial
risk, for whom MRI is cost-effective. A prospective rando-
mized trial in women with increased breast cancer risk,
taking breast density into account, will give robust
evidence on which screening tool, MRI or mammography,
is best suited for a particular woman. These issues are
addressed in the Familial MRI Screening study (FaMRIsc).
Methods/Design
Trial design
The FaMRIsc study is a multicentre, randomized con-
trolled trial (RCT), with balanced randomisation (1:1),
and a parallel group design conducted in the Netherlands.
The study is in compliance with the Helsinki declaration
and ethical approval has been granted on 8 November
2010 by the Institutional Review Board of the Erasmus
University Medical Centre, Rotterdam, the Netherlands
(reference-number: MEC-2010-292).
Participants
Eligible participants are women aged 30–55 years with a
cumulative lifetime risk (CLTR) of >20% because of a
familial predisposition according to the modified tables
of Claus [1,27] or as assessed at a Clinical Genetics
Centre. BRCA1 and/or BRCA2 mutation carriers or
women with a 50% likelihood of such a mutation are
excluded, since MRI screening is already advised for
these women by the American Cancer Society (ACS), the
American College of Radiologists (ACR), the United
Kingdom’s NICE guideline and the European guideline of
the European Society of breast imaging (EUSOBI)
[18,28-30]. Exclusion criteria are previous invasive cancer
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(potentially of influence on survival data), and a contra-
indication for contrast-enhanced MRI (decreased creati-
nin clearance, metal implants or claustrophobia).
Study settings
Participants are recruited from outpatient breast or fam-
ily cancer clinics at all eight academic medical centres in
the Netherlands and the Netherlands Cancer Institute/
Antoni van Leeuwenhoek Hospital (Additional file 1).
Women who are already in a screening programme be-
cause of an increased familial risk and meeting inclusion
criteria are sent study information 2 weeks before a
scheduled visit. Women who meet all criteria and visit
the outpatient clinic for an initial screening are given in-
formation on site.
Interventions
After informed consent is obtained participants are ran-
domized through a computer-generated randomization
sequence with stratification for centre, in one of the two
groups.
Group 1 receives screening according to the 2012
Dutch guidelines [17] with yearly mammography and
clinical breast examination (CBE).
Group 2 is screened with yearly MRI and CBE, and mam-
mography biennially (Figure 1). Additional investigations
are performed if deemed necessary due to findings at clin-
ical examination, on mammography or MRI. Mammog-
raphy still has a place in both arms, since DCIS is generally
easier to detect with mammography [8,10,31-33], although
in one study MRI was found to detect more aggressive
grade III DCIS than mammography [34]. In the interven-
tion arm however, the frequency of mammography is
reduced from annually to biennially. DCIS not detected by
MRI will most likely be low-grade, progress slowly, and be
detected by the next mammographic examination. Leaving
out mammography every other year seems safe in the MRI
arm and may prevent over diagnosis of low-grade DCIS.
Mammographic examination is done using full field digital
mammography (FFDM). All examinations are scored in a
standardized way, according to the Breast Imaging Report-
ing and Data System (BI-RADS) mammography classifica-
tion of the American College of Radiology [30]. To
determine mammographic density an automated breast
density measurement is done on raw data of the first FFDM
of all participants [35,36]. Dynamic breast MRI with
gadolinium-containing contrast medium is performed
according to standard protocol. In premenopausal women,
the MRI is performed between day 5 and 20 of the men-
strual cycle [37].
Outcomes
Primary endpoints are the number and stage of detected
breast cancers, both DCIS and invasive, in each arm.
Secondary endpoints are the false-positive results in the
screening arms, and the sensitivity and positive predict-
ive value of both screening strategies. Furthermore, cost-
effectiveness and breast cancer mortality reduction of
both strategies will be assessed. All analyzes will also be
performed stratified for mammographic density.
A positive screening test is defined as a mammographic
or MRI examination with a BI-RADS score of 0, 3, 4, or 5
and/or a clinical breast examination classified as ‘suspi-
cious’. Interval cancers are defined as tumours diagnosed
after a negative screening examination but before the next
scheduled screening examination. Sensitivity is calculated
as the number of screen-detected tumours divided by the
total of screen-detected and interval tumours. The positive
predictive value of a screening strategy is calculated as the
proportion of women with a positive screening test, which
after pathology indeed proved to be breast cancer.
Prospective assessment of mortality reduction requires
a very lengthy follow-up and a large study population,
which may not be feasible. To study this issue we will
start with a less costly and time-consuming approach
and estimate mortality reduction through a micro-
simulation model: MISCAN, a well-validated micro-
simulation model, originally developed to estimate the
cost-effectiveness of the population-based screening pro-
gram in the Netherlands [38-40]. In the model, the
natural history of breast cancer is modelled as a progres-
sion through 5 pre-clinical and invasive disease stages.
At each pre-clinical stage, a tumour may either be clinic-
ally diagnosed or grow into the next pre-clinical stage.
Screening may detect the tumour in a preclinical stage.
Transition probabilities, stage durations and survival
after clinical diagnosis or screen detection are based on
data from the Dutch nation-wide screening program
[41,42]. The improvement of prognosis after detection
by screening is based on the long-term effects of Swed-
ish trials [43-45]. A detailed description of the model
has been published previously [39].
We will develop a family history risk model by using
the number of women enrolled in the study, the age dis-
tribution at entry of the study, the duration of follow-up
and the screening protocol, attendance and sensitivity of
different screenings methods as inputs. The model will
be calibrated using the number of screens, the number
of screen detected cancers and interval cancers, the
stage distribution and the age at diagnosis. Likelihood
ratio tests will be used to compare the goodness of fit.
Using the calibrated model, predictions of the number
of screens, number of screen detected and interval can-
cers, the stage distribution, the mortality reduction and
the life years gained will be made for the different
screening arms in the study.
A cohort of 5 million women will be simulated. All
costs and effects will be predicted for a life-time follow-
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up. The costs will be presented in European currency
(€). Cost-effectiveness ratios will be expressed as cost
per life year gained (LYG). Costs and effects will be dis-
counted at an annual rate of 3.5%.
Sample size/power calculation
Our primary aim is to detect a difference in tumour stage
between the intervention and the current practice group.
In the Dutch MRI Screening Study (MRISC) study, con-
ducted from 1999 to 2007, over 1500 women with familial
risk were included in the 6 participating centres [11]. The
incidence rate in this risk group was 7/1000 women years
screened. Since the FaMRIsc study will have three more
participating centres we intend to include 2000 women.
We expect to detect about 50 breast cancers (both DCIS
and invasive) in 4 years. With this number we are able to
detect a difference in tumour size of 8 mm (SD tumour
size: 9 mm) as statistically significant (two sided alpha
=0.05) with a power of 80%. Eight mm is considered to be
a clinically relevant difference.
Stopping guidelines
The accrual will be evaluated after two years. If adequate
inclusion numbers cannot be achieved, appropriate
measures will be taken in the remaining two years, con-
sisting of expansion of the number of participating cen-
tres or longer continuation of the study.
Statistical methods
Primary outcome will be incidence and the difference in
mean tumour size at diagnosis between the two arms. If
normally distributed, this will be tested by means of the
independent samples (unpaired) t-test. If not normally
distributed, medians will be estimated and differences
between distributions will be tested with the non-
parametric Mann–Whitney U test.
Breast cancer incidence rates will be calculated as the
total number of breast cancers detected per 1000
woman-years at risk. This will be calculated both includ-
ing and excluding DCIS. Differences between these pro-
portions will be compared using a chi-square test or
Fisher’s exact test as appropriate.
All tests will also be performed stratified by mammo-
graphic density to examine the influence of density on
the efficacy of MRI screening versus usual care. The
influence of breast density on detection rates, tumour
stage and false positive results in both arms will be ana-
lysed by means of analysis of variance (ANOVA).
Exclusion criteria
BRCA1/2 mutation carrier
50% likelihood of such a mutation
Contra-indication MRI
Invasive carcinoma in medical history
Intervention
Yearly MRI + CBE
Year 1 & 3: mammography 
Breast density measurement 
Current practice
Yearly mammography + CBE
Breast density measurement 
Randomized 1:1
Inclusion criteria
CLTR breast cancer ≥20%
30-55 years 
Informed consent obtained 
Figure 1 Flow diagram Familial MRI Screening Study (FaMRIsc). CLTR: Cumulative Lifetime Risk, MRI: Magnetic Resonance Imaging, CBE: Clinical
Breast Examination.
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Discussion
Twenty-five percent of all breast cancers occur before
age 50 and especially familial breast cancer is seen at
younger ages [2]. A randomized controlled trial can pro-
vide the best evidence for any breast cancer mortality
reduction attributable to digital mammography or MRI
screening in this population.
Studies that offered MRI and mammography screening
simultaneously have several shortcomings due to their
paired design. Sensitivity of neither test without the
other can be assessed. Nor the stage in which either test
separately would have detected tumours.
With the results of our study we will be able to esti-
mate the mortality reduction for screening women with
familial risk with either digital mammography or add-
itional MRI.
Furthermore, we will be able to assess whether mortal-
ity reduction by earlier detection differs with increasing
breast density between screening with digital mammog-
raphy or with additional MRI.
Breast density may be a key discriminator for choosing
the optimal screening strategy below age 50 years for
women with familial risk. If we can assess this, persona-
lized cancer screening can be offered, based on a
woman’s age, risk and breast density. This may optimize
mortality reduction, whilst possibly decreasing over diag-
nosis. Compliance to screening will be best if there is
convincing evidence that the most effective tool with the
lowest side-effects is offered.
Additional file
Additional file 1: Academic Medical Centres participating in the
FaMRIsc in the Netherlands.
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